Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.

ABSTRACT:

Aims

Co-primary objectives were to evaluate dalcetrapib (JTT-705/RO4607381), which targets cholesteryl ester transfer protein (CETP), effects on high-density lipoprotein cholesterol (HDL-C) in participants with coronary heart disease or risk equivalents and to evaluate potential changes in mesenteric lymph nodes.

Methods and results

Double-blind trial with participants randomized (2:1) to dalcetrapib 900 mg/day (higher than 600 mg phase III dose) or placebo, both with atorvastatin, for 24 weeks (n = 135; one without post-baseline efficacy data was excluded from intent-to-treat population); a subset continued for 24-week extension (n = 77). Lipid changes and safety parameters were assessed. Mesenteric lymph nodes were evaluated by magnetic resonance imaging. Dalcetrapib incre

SUBMITTER: Stein EA 

PROVIDER: S-EPMC2821630 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature